P965: Stem-Cell Mobilization With Cyclophosphamide 4 G/M2 Allows Collection of High Numbers of Cd34+ Cells After Dara-VTD Induction for Multiple Myeloma

Abstract

Quadruplet induction with Daratumumab, Bortezomib, Thalidomide and Dexamethasone (Dara-VTd) has become the standard treatment for transplant-eligible newly diagnosed multiple myeloma patients (NDMM). Despite improved response rates compared to VTd, concerns with stem-cell mobilization and collection emerged in CASSIOPEIA trial. Indeed, after a mobilization approach based on cyclophosphamide (2 to 3 g/m 2 ) and granulocyte colony-stimulating factor (G-CSF) 10 μg/kg/day, patients treated with Dara-VTd experienced a greater use of plerixafor as well as a lower median number of collected CD34 + cells/Kg.